Novartis taps Abogen’s RNA platform in potential $7.8B deal BioWorld 21:38 Fri, 02 Oct Article paywall
FDA Approves First mRNA Flu Vaccine Ahead of Upcoming Season KNOE 18:21 Wed, 30 Sep Flu Pandemics All sources
Divergent trial results on cancer vaccines have the field grappling with hard questions STAT 6d Cancer Treatment Cancer Health & Fitness
False claim linking Covid jabs to 'turbo cancer' fuels vaccine fears in Indonesia AFP Fact Check 4d Facebook Covid Moderna Vaccine
Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager Manufacturing Chemist 6d Abogen T-Cells Biotechnology
International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases ecancer 5d CAR-T The Lancet Health & Fitness
Study explains why cancer immunity declines faster in males News-Medical.Net 2d Cancer Treatment Cancer Science
Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager Manufacturing Chemist 6d Abogen mRNA Biotechnology
Yonsei's L1CAM-targeted CAR-T eliminates ovarian tumors in preclinical study Korea Biomedical Review 3d CAR-T Cancer Cancer Treatment
